

Zhuoming Liu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1532080/zhuoming-liu-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54
papers

3,475
citations

27
h-index

57
g-index

57
ext. papers

5,543
ext. citations

18.9
avg, IF

5.76
L-index

#	Paper	IF	Citations
54	TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. <i>Science Immunology</i> , 2020 , 5,	28	531
53	Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. <i>Cell Host and Microbe</i> , 2021 , 29, 44-57.e9	23.4	525
52	Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. <i>Cell Host and Microbe</i> , 2021 , 29, 477-488.e4	23.4	423
51	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021 , 184, 2332-2347.e16	50.4	316
50	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020 , 28, 475-485.e5	23.4	252
49	SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. <i>Nature</i> , 2021 , 597, 97-102	50.4	118
48	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 32105-32113	11.5	96
47	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021 , 597, 103-108	50.4	94
46	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021 , 596, 103-108	50.4	91
45	Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 20803-20813	11.5	87
44	Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study. <i>Annals of Internal Medicine</i> , 2021 , 174, 1572-1585	8	80
43	Herpes simplex virus 1 UL47 interacts with viral nuclear egress factors UL31, UL34, and Us3 and regulates viral nuclear egress. <i>Journal of Virology</i> , 2014 , 88, 4657-67	6.6	49
42	Role of Host Cell p32 in Herpes Simplex Virus 1 De-Envelopment during Viral Nuclear Egress. <i>Journal of Virology</i> , 2015 , 89, 8982-98	6.6	44
41	Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization 2021 ,		44
40	Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 2021 ,		44
39	Role of herpes simplex virus 1 immediate early protein ICP22 in viral nuclear egress. <i>Journal of Virology</i> , 2014 , 88, 7445-54	6.6	42
38	Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell. <i>Cell Reports</i> , 2021 , 36, 109364	10.6	42

37	Landscape Analysis of Escape Variants Identifies SARS-CoV-2 Spike Mutations that Attenuate Monoclonal and Serum Antibody Neutralization. <i>SSRN Electronic Journal</i> ,	1	41
36	TMPRSS2 and TMPRSS4 mediate SARS-CoV-2 infection of human small intestinal enterocytes		35
35	Herpes simplex virus 1 protein kinase Us3 and major tegument protein UL47 reciprocally regulate their subcellular localization in infected cells. <i>Journal of Virology</i> , 2011 , 85, 9599-613	6.6	34
34	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 2021 ,		34
33	Sulfated glycosaminoglycans and low-density lipoprotein receptor contribute to <i>Clostridium difficile</i> toxin A entry into cells. <i>Nature Microbiology</i> , 2019 , 4, 1760-1769	26.6	32
32	Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition 2020 ,		32
31	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. <i>Immunity</i> , 2021 , 54, 2399-2416.e6	32.3	30
30	Herpes simplex virus 1 protein kinase Us3 phosphorylates viral dUTPase and regulates its catalytic activity in infected cells. <i>Journal of Virology</i> , 2014 , 88, 655-66	6.6	28
29	Herpes Simplex Virus 1 Recruits CD98 Heavy Chain and β Integrin to the Nuclear Membrane for Viral De-Envelopment. <i>Journal of Virology</i> , 2015 , 89, 7799-812	6.6	27
28	A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants. <i>Immunity</i> , 2021 , 54, 2159-2166.e6	32.3	27
27	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.. <i>Science</i> , 2022 , 375, eabm8143	33.3	23
26	Germinal centre-driven maturation of B cell response to mRNA vaccination.. <i>Nature</i> , 2022 ,	50.4	15
25	Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody 2021 ,		14
24	Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. <i>SSRN Electronic Journal</i> , 2020 , 3606354	1	12
23	Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2 2020 ,		12
22	Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape 2021 ,		12
21	Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 2020 ,		10
20	Role of the nuclease activities encoded by herpes simplex virus 1 UL12 in viral replication and neurovirulence. <i>Journal of Virology</i> , 2014 , 88, 2359-64	6.6	9

19	A public vaccine-induced human antibody protects against SARS-CoV-2 and emerging variants 2021 ,		9
18	JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis 2021 ,		8
17	Human immunoglobulin from transchromosomal bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. <i>Human Vaccines and Immunotherapeutics</i> , 2021 , 1-10	4.4	8
16	SARS-CoV-2 Viral RNA Shedding for More Than 87 Days in an Individual With an Impaired CD8+ T Cell Response. <i>Frontiers in Immunology</i> , 2020 , 11, 618402	8.4	8
15	Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry 2021 ,		7
14	Defining the risk of SARS-CoV-2 variants on immune protection.. <i>Nature</i> , 2022 ,	50.4	7
13	Structural mechanism of SARS-CoV-2 neutralization by two murine antibodies targeting the RBD. <i>Cell Reports</i> , 2021 , 37, 109881	10.6	6
12	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion		6
11	A potentially neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope 2021 ,		6
10	Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters. <i>MBio</i> , 2021 , 12, e0239521	7.8	5
9	Imprinted antibody responses against SARS-CoV-2 Omicron sublineages		5
8	Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status. <i>Current Pharmaceutical Design</i> , 2019 , 25, 4251-4263	3.3	4
7	Multivalent designed proteins protect against SARS-CoV-2 variants of concern 2021 ,		4
6	Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.. <i>MBio</i> , 2022 , e0344221	7.8	3
5	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice.. <i>Science Translational Medicine</i> , 2022 , 14, eabn1252	17.5	3
4	JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis.. <i>MBio</i> , 2022 , e0337721	7.8	2
3	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains 2021 ,		2
2	Human immunoglobulin from transchromosomal bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants		1

- 1 Temporal Increase in Neutralization Potency of SARS-CoV-2 Antibodies and Reduced Viral Variant Escape after Sputnik V Vaccination